Newsroom Inflammatix in the news Leading Stanford Alumni Scientists and Physicians Launch StartX Med COVID-19 Task Force Mar 18, 2020 Inflammatix named to Fierce 15 MedTech list Mar 9, 2020 New Technologies Can Step Up Fight Against Antimicrobial Resistance and Sepsis Jan 10, 2020 Inflammatix raises $32M, plus a BARDA contract, for its point-of-care infection diagnostics Jan 10, 2020 Inflammatix Raises $32M in Series C Financing Jan 10, 2020 Genetic platform takes the guesswork out of catching infections Dec 4, 2019 BARDA awards contract to Inflammatix for innovative diagnostic test systems Nov 18, 2019 BARDA backs Inflammatix test to improve antibiotic use Nov 15, 2019 Inflammatix Nabs $6M from BARDA to Develop POC Acute Infection Diagnostic Nov 15, 2019 Inflammatix scores BARDA contract for infection tests Nov 14, 2019 How $6 million could help a small Peninsula company spot deadly infections Nov 14, 2019 Inflammatix Inks BARDA Contract for up to $72M Nov 14, 2019 Older NewsRecent News Inflammatix sepsis test scores FDA breakthrough device designation Nov 28, 2023 Inflammatix Aims for 2024 Launch of 30-Minute Sepsis and Acute Infection Test Nov 28, 2023 Your medical devices are getting smarter. Can the FDA keep them safe? Oct 9, 2023 Older NewsRecent News Inflammatix Checks off All the Right Boxes with Investors Mar 19, 2021 Inflammatix nets $102M to advance its immune system tests for infectious diseases Mar 16, 2021 Infection-detection system from Peninsula company scores $102M, aims to hit market this year Mar 16, 2021 A Bright Future Ahead for Novel Markers of Infection Dec 15, 2020 Inflammatix Awarded $7.4M in Additional BARDA Funding for POC System, Acute Infection Test Oct 29, 2020 Inflammatix Moving Into Coronavirus Test Market With Gene Expression Host Response Platform Oct 8, 2020 Older NewsRecent News Press releases Nov 11, 2021 Inflammatix Awarded $1.7 Million Grant From National Institutes of Health (NIH) Mar 16, 2021 Inflammatix Secures $102 Million in Series D Financing Led by D1 Capital Partners to Commercialize Novel Host Response Diagnostics Oct 29, 2020 Inflammatix Announces $7.4 Million in Additional BARDA Funding to Advance ViraBac EZ Acute Infection Test Sep 29, 2020 DARPA Awards Inflammatix up to $1.1 Million to Develop Diagnostic that Predicts COVID-19 Severity Risk Apr 29, 2020 Study Demonstrates Substantial Cost Savings in Health Economic Model of the Inflammatix Host-Response Test for Sepsis Apr 16, 2020 Inflammatix Appoints João Fonseca, Ph.D., as Chief Technology Officer Older Press ReleasesRecent Press Releases Machine learning blogs Podcasts Diagnosing Infection with Ljubomir Buturovic from Inflammatix December 2023 Advances in Sepsis Diagnostics: the HostDx Sepsis Platform May 2018 Media Contact [email protected]
Inflammatix raises $32M, plus a BARDA contract, for its point-of-care infection diagnostics Jan 10, 2020
Infection-detection system from Peninsula company scores $102M, aims to hit market this year Mar 16, 2021
Inflammatix Awarded $7.4M in Additional BARDA Funding for POC System, Acute Infection Test Oct 29, 2020
Inflammatix Moving Into Coronavirus Test Market With Gene Expression Host Response Platform Oct 8, 2020
Mar 16, 2021 Inflammatix Secures $102 Million in Series D Financing Led by D1 Capital Partners to Commercialize Novel Host Response Diagnostics
Oct 29, 2020 Inflammatix Announces $7.4 Million in Additional BARDA Funding to Advance ViraBac EZ Acute Infection Test
Sep 29, 2020 DARPA Awards Inflammatix up to $1.1 Million to Develop Diagnostic that Predicts COVID-19 Severity Risk
Apr 29, 2020 Study Demonstrates Substantial Cost Savings in Health Economic Model of the Inflammatix Host-Response Test for Sepsis
